These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 28215927)

  • 1. Will drug companies' price-transparency efforts fall short?
    Furlow B
    Lancet Oncol; 2017 Mar; 18(3):288. PubMed ID: 28215927
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmaceutical companies' variation of drug prices within and among countries can improve long-term social well-being.
    Lichtenberg FR
    Health Aff (Millwood); 2011 Aug; 30(8):1539-44. PubMed ID: 21821571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hospital campaign against drug price increases is making a dent.
    Wagner M
    Mod Healthc; 1992 Mar; 22(10):30. PubMed ID: 10116546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceutical expenditure control in Europe: time to move from pricing to budgeting?
    Garattini L; Padula A
    J R Soc Med; 2020 Mar; 113(3):93-97. PubMed ID: 31858868
    [No Abstract]   [Full Text] [Related]  

  • 5. Former banker who hiked price of drug refuses to speak at congressional hearing.
    Dyer O
    BMJ; 2016 Feb; 352():i765. PubMed ID: 26850070
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug prices: is the sky the limit?
    Pasternak J
    Einstein (Sao Paulo); 2016; 14(3):11-13. PubMed ID: 27759815
    [No Abstract]   [Full Text] [Related]  

  • 7. The high cost of medicines in Ireland. Is it time to change the pricing mechanism?
    Tilson L; McGowan B; Bennett K; Barry M
    Eur J Health Econ; 2004 Dec; 5(4):341-4. PubMed ID: 15452737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'We should question the power of drug companies'.
    Radcliff M
    Nurs Times; 2008 Jul 8-14; 104(27):52. PubMed ID: 18683392
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug price controls will cripple research and development, pharmaceutical executives tell Congress.
    Am J Hosp Pharm; 1994 May; 51(9):1132, 1135-6, 1139. PubMed ID: 8042629
    [No Abstract]   [Full Text] [Related]  

  • 10. Is there transparency in the pricing of medicines in the South African private sector?
    Bangalee V; Suleman F
    S Afr Med J; 2018 Feb; 108(2):82-83. PubMed ID: 29429435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Without proportions about drugs].
    Strifeldt HP
    Tidsskr Nor Laegeforen; 2003 Apr; 123(7):970. PubMed ID: 12737077
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug companies' patient-assistance programs--helping patients or profits?
    Howard DH
    N Engl J Med; 2014 Jul; 371(2):97-9. PubMed ID: 25006717
    [No Abstract]   [Full Text] [Related]  

  • 14. Petition fails to reverse massive price rise for AIDS drug.
    Check E
    Nature; 2004 Aug; 430(7001):715. PubMed ID: 15306778
    [No Abstract]   [Full Text] [Related]  

  • 15. [A bitter pill].
    Haug C
    Tidsskr Nor Laegeforen; 2003 Mar; 123(5):601. PubMed ID: 12683179
    [No Abstract]   [Full Text] [Related]  

  • 16. Regulating the pharmaceutical industry. Authors seem to have misunderstood pharmaceutical price regulation scheme.
    Read P
    BMJ; 1998 Jan; 316(7126):226; author reply 228. PubMed ID: 9468700
    [No Abstract]   [Full Text] [Related]  

  • 17. Price-cost margin in the pharmaceutical industry. Empirical evidence from Finland.
    Linnosmaa I; Hermans R; Hallinen T
    Eur J Health Econ; 2004 Jun; 5(2):122-8. PubMed ID: 15452748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
    Stargardt T; Schreyögg J; Busse R
    Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs for chronic diseases: getting the price right.
    The Lancet Diabetes Endocrinology
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):959. PubMed ID: 27886742
    [No Abstract]   [Full Text] [Related]  

  • 20. Companies use value-based pricing for single-source off-patent drugs.
    Thompson CA
    Am J Health Syst Pharm; 2016 Mar; 73(6):350, 352, 355. PubMed ID: 26953277
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.